Vertex launches pivotal trial for stem-cell derived islet therapy
On Monday, Vertex made a monumental announcement. Their Phase 1/2 trial for VX-880 is converting to a Phase 1/2/3 pivotal…
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential…
Stem Cell-Derived Islets Show Promise In Another Study
A new study published in Cell and summarized in Nature has shown positive results using stem cell-derived islets to restore…
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
A New Shot on Goal for Cell Therapies In T1D
Eledon Pharmaceuticals announces new funding from the T1D Fund and the launch of their clinical trial for tegoprubart in T1D.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D Collaboration Leads to Next-Generation Cell Therapy Research
Aspect and Novo Nordisk announce a partnership, using Aspect’s bioprinting technology and Novo Nordisk’s expertise, to develop treatments for diabetes.
Cell Therapy Moves Forward Across the Pipeline
Beta cell replacement therapies aim to overcome the obstacles to realize their potential, but several approaches are making them a…
Verapamil Slows Type 1 Diabetes Progression in Newly Diagnosed Children and Teens
The CLVer study found that newly diagnosed individuals on verapamil were making more insulin one year after diagnosis than those…
“I Really Love Type 1 Diabetes Research, and I’m Not Going Back”
A goal of David Alagpulinsa, Ph.D., is to contribute to a treatment that makes people with type 1 diabetes live…
